Naltrexone

URI: https://gptkb.org/entity/Naltrexone

GPTKB entity

Predicate	Object
gptkbp:instanceOf	gptkb:drug opioid
gptkbp:approvalYear	1984
gptkbp:approvedBy	gptkb:FDA
gptkbp:ATCCode	gptkb:N07BB04
gptkbp:bioavailability	5-40% (oral)
gptkbp:brand	gptkb:Vivitrol gptkb:Depade gptkb:ReVia
gptkbp:CASNumber	16590-41-3
gptkbp:category	gptkb:WHO_essential_medicine
gptkbp:chemicalFormula	C20H23NO4
gptkbp:contraindication	liver failure acute hepatitis
gptkbp:developedBy	gptkb:Endo_Laboratories
gptkbp:discoveredIn	1963
gptkbp:eliminationHalfLife	4 hours
gptkbp:excretion	urine
gptkbp:hasEnantiomer	gptkb:levallorphan
https://www.w3.org/2000/01/rdf-schema#label	Naltrexone
gptkbp:IUPACName	(4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,3,4,4a,5,6,7,7a-octahydro-1H-benzo[f]isoquinolin-7-one
gptkbp:legalStatus	prescription only
gptkbp:marketedAs	gptkb:United_States
gptkbp:mechanismOfAction	blocks opioid receptors
gptkbp:MeSH_ID	D009376
gptkbp:metabolism	liver
gptkbp:molecularWeight	341.4 g/mol
gptkbp:pregnancyCategory	C (US) B3 (Australia)
gptkbp:proteinBinding	21%
gptkbp:PubChem_CID	gptkb:CHEMBL1423 5360515 DB00704
gptkbp:relatedTo	gptkb:methadone gptkb:naloxone gptkb:buprenorphine
gptkbp:routeOfAdministration	oral intramuscular
gptkbp:sideEffect	nausea dizziness fatigue headache
gptkbp:synonym	N-cyclopropylmethyl-14-hydroxynormorphinone
gptkbp:UNII	2S7953Q994
gptkbp:usedFor	alcohol dependence opioid dependence
gptkbp:bfsParent	gptkb:Opiate
gptkbp:bfsLayer	5